Immunosuppression reduction when administering a booster dose of the BNT162b2 mRNA SARS-CoV-2 vaccine in kidney transplant recipients without adequate humoral response following two vaccine doses: protocol for a randomised controlled trial (BECAME study)

IntroductionInadequate antibody response to mRNA SARS-CoV-2 vaccination has been described among kidney transplant recipients. Immunosuppression level and specifically, use of antimetabolite in the maintenance immunosuppressive regimen, are associated with inadequate response. In light of the severe...

Full description

Saved in:
Bibliographic Details
Published in:BMJ open 2021-10, Vol.11 (10), p.e055611
Main Authors: Yahav, Dafna, Rozen-Zvi, Benaya, Mashraki, Tiki, Atamna, Alaa, Ben-Zvi, Haim, Bar-Haim, Erez, Rahamimov, R
Format: Article
Language:English
Subjects:
Acids
Antibodies
BNT162 Vaccine
Coronaviruses
COVID-19
COVID-19 Vaccines
Equivalence Trials as Topic
Humans
immunology
Immunosuppression Therapy
Infections
Infectious Diseases
Kidney Transplantation
Kidney transplants
Mortality
mRNA vaccines
Observational Studies as Topic
Patients
Proteins
Randomized Controlled Trials as Topic
renal transplantation
RNA, Messenger
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Treatment Outcome
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!